Research suggests that cranberry (Vaccinium macrocarpon) helps maintain urinary tract health. Bacterial adhesion to the uroepithelium is the initial step in the progression to development of a urinary tract infection. The bacterial anti-adhesion activity of cranberry proanthocyanidins (PACs) has been demonstrated in vitro. Three different cranberry extracts were developed containing a standardized level of 36 mg of PACs. This randomized, double-blind, placebo controlled, ex vivo, acute study was designed to compare the anti-adhesion activity exhibited by human urine following consumption of three different cranberry extracts on uropathogenic P-fimbriated Escherichia coli in healthy men and women. All three cranberry extracts significantly increased anti-adhesion activity in urine from 6 to 12 hours after intake of a single dose standardized to deliver 36 mg of PACs (as measured by the BL-DMAC method), versus placebo.
Urinary tract infections (UTIs) are one of the most common bacterial infections in females, with more than half of women having experienced such a problem at least once in their lifetime. Bacterial adherence to mucosal cells is the initial step in the development of infection, with 70−95% of all uncomplicated urinary tract infections attributed to uropathogenic Escherichia coli [1] . Adherence of E. coli to uroepithelial cells (UEC) is facilitated by virulence factors, such as type 1 and P-fimbrial adhesins, which target host receptors. Type-1 E. coli has fimbriae that bind to mannose-like receptors on uroepithelial cell surfaces. P-fimbriated E. coli attach to oligosaccharide receptor sequences (αGal(1→4)β-Gal) on cell surfaces in the urinary tract [2] . The P-fimbriae are found in 60% of the strains of E. coli causing cystitis (urinary bladder infection) and 80% of the strains causing pyelonephritis (kidney infection) [1] . The ability of such attached bacteria to withstand forces caused by rinsing flows is not only given by the properties of the adhesin-receptor interactions, but is also strongly affected by the biomechanical properties of these organelles [3] . In recent decades, studies have targeted the prevention of bacterial attachment, focusing on inhibitors targeting the adhesion process, i.e. carbohydrate derived competitive inhibitors for adhesionreceptor interactions [4] . Multiple assays have been developed to examine bacterial anti-adhesion activity (AAA), including hemagglutination, Gal-Gal bead agglutination and epithelial cell adherence [5] . Previous studies have demonstrated the anti-adhesion activity of cranberry in various cell models [6] [7] [8] .
Research suggests that compounds in cranberry (Vaccinium macrocarpon) inhibit bacterial adherence to UEC. The antiadhesion activity of cranberry proanthocyanidins (PACs) has been demonstrated in vitro in the various assays cited above. However, PACs exhibit poor bioavailability. Some in vitro investigations suggest that smaller PAC oligomers are absorbed in small quantities through models of the intestinal epithelium [9] . Other data suggest that gut microflora significantly degrade polymeric PAC to aromatic acids or monomer units, which may be absorbed in more significant quantities [10] . The procyanidin A2 dimer was also quantified in plasma and urine following cranberry juice ingestion, with an 11 hour T max , confirming catabolism in the lower GI tract by gut microbiota [11] .
A Cochrane review published by Jepson et al. in 2012 [12] suggests that cranberry juice is less effective than previously indicated. Given the large number of dropouts/withdrawals from studies (mainly attributed to the acceptability of consuming cranberry products, particularly juice, over long periods), and the evidence that the benefit for preventing UTI is small, Jepson and coworkers concluded that cranberry juice cannot currently be recommended for the prevention of UTIs. These investigators suggested that other preparations (such as powders) need to be quantified using standardized methods to ensure the potency, and contain enough of the 'active' ingredient, before being evaluated in clinical studies or recommended for use [12] . Research is underway to identify antiadhesive metabolites or induced compounds in urine following cranberry consumption to aid in measuring compliance in clinical trials. Currently, measuring bacterial anti-adhesion activity in human urine following V. macrocarpon consumption serves as an indirect way to assess the effectiveness of cranberry consumption.
In pursuing this objective, we have developed three different cranberry extracts containing a standardized level of PACs, which is the current marker accepted by the industry, in order to deliver 36 mg of PACs, as described in previous studies [6, 7, 13] . However, despite all the efforts made to measure PACs accurately and due to their chemical complexity, there still are some controversies regarding the PAC standardization of cranberry extracts in the NPC Natural Product Communications 2015 Vol. 10 No. 7 1215 -1218 market today [14] . The currently accepted method to measure PAC levels used by industry is the inter-laboratory validated BL-DMAC method [15] . The accepted method to measure the anti-adhesion activity of the PACs in cranberry products and urine following cranberry consumption is the mannose resistant hemagglutination (MRHA) assay [16] . Bacterial attachment to mucosal cells and bacteria-mediated hemagglutination involve similar mechanisms, and hemagglutination has been successfully utilized for many years as a surrogate test for the measurement of bacterial adhesion [17] [18] [19] . Agglutination of erythrocytes (hemagglutination) by E. coli occurs when the bacterial fimbriae bind to the surface of the blood cell: P-type uropathogenic E.coli (UPEC) induces human A+ or O+ erythrocytes MRHA. P-type E. coli recognizes and binds to a specific galactosyl-galactose structure on cells and human red blood cells (HRBCs) which is part of the P blood group antigens. In the hemagglutination test used to evaluate cranberry for anti-adhesion activity, the whole cranberry or fractions are pre-incubated with P-type E. coli prior to incubation with HRBCs. The minimum inhibitory concentration (MIC) of cranberry or PAC required to prevent hemagglutination is recorded as the concentration that prevents bacterial adhesion of P-type E. coli [6, 16, [20] [21] [22] [23] [24] .
This randomized, double-blind, placebo controlled, ex vivo, acute study was designed to compare the anti-adhesion activity exhibited by human urine upon consumption of three different cranberry extracts on uropathogenic P-fimbriated E. coli.
Test products (HiPAC® BL-DMAC 3.6, Cranberry Extract (CE)15, Cysticran® BL-DMAC 10 and placebo) were administered in random order to 20 subjects (10 men and 10 women) in a crossover, blinded study design. The test products were standardized so that a 2-capsule intake delivered 36 mg of PACs. During the 7-day run-in period, study participants were trained on clean-catch urine collection procedures, as well as the time intervals for urine collection and the appropriate procedures for storing their urine samples. Urine (approximately 25 mL) was collected (clean-catch) by each participant prior to product consumption (0 h) and at 6, 9, 12, 24 and 36 h following product consumption, and immediately frozen. On urine collection days, additional fluid consumption was standardized to 240 mL every 4 h to avoid dilution of urine samples and allow for detection of AAA, if present.
The primary outcome measure was the P-fimbriated E.coli AAA of urinary samples collected from the participants in the study. The IC 50 , in vitro of all three powders standardized to 3.6% PACs was the same: 0.23 mg/mL.
Ex vivo anti-adhesion activity was measured using participants' urine following cranberry ingredients consumption. Twenty participants (1:1 gender ratio) were tested during placebo and cranberry phases in a crossover design with AAA measured immediately prior to and at 5 time points (6, 9, 12, 24 and 36 h) after consumption of the product. No AAA was detected in urine samples prior to product consumption. Urinary pH averaged 6.2, eliminating a bacteriostatic effect. Two participants that were randomized to the CE15 group were removed from the analysis because they were showing AAA at 0 h.
The average rate of anti-adhesion activity observed in urine, represented as a sum of all anti-adhesion responses is represented Figure 1 and individual data and statistics are detailed Table 1 .
HiPAC®, Cysticran® and CE15 had a significantly higher AAA than placebo [score over all time periods for all participants combined (ANOVA, p<0.001)]. Both time and treatment demonstrated significant differences (p<0.001). 
Ex vivo anti-adhesion effect of cranberry extracts
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By time period, the AAA of HiPAC®, Cysticran® and CE 15 was significantly higher than placebo at 6, 9 and 12 h after ingestion ( Figure 1 , Table 1 ), as demonstrated using multiple comparisons using least square differences (LSD). There was no significant difference in AAA between HiPAC®, Cysticran® and CE 15 and placebo at collection times 0 (pre), 24 and 36 h. At 9 h, AAA of Cysticran® was significantly higher than placebo, HiPAC® and CE 15 (p=0.041). At 9 h, in the urine samples of the participants taking CE15, 7 out of 18 exhibited a 50% reduction in HRBC agglutination (38.9%) and 5 out of 18 exhibited a 100% reduction in HRBC agglutination (27.8%). At 9 h, in the urine samples of the participants taking Cysticran®, 9 out of 20 exhibited a 50% reduction in HRBC agglutination (45%) and 10 out of 20 exhibited a 100% reduction in HRBC agglutination (50%). At 9 h, in the urine samples of the participants taking HiPAC®, 7 out of 20 exhibited a 50% reduction in HRBC agglutination (55%) and 5 out of 20 exhibited a 100% reduction in HRBC agglutination (25%). Placebo ingestion resulted in no significant AAA at any time period. There was no significant gender difference in AAA response to any of the ingredients tested versus placebo (data not shown).
Results of this study demonstrate that three cranberry extracts inhibit adhesion of P-fimbriated E.coli in an in vitro HRBC assay, and that a similar effect was observed ex vivo when testing the urine of participants following consumption of the same cranberry extracts. CE 15, Cysticran® BL-DMAC 10 and HiPAC® BL-DMAC 3.6 all contributed to a significant increase in anti-adhesion activity in urine from 6 to 12 hours after intake upon consumption of a single dose standardized to deliver 36 mg of PACs (as measured by the BL-DMAC method), versus placebo. These cranberry products, when taken on a daily basis, may offer some benefit for maintenance of urinary tract health.
Experimental
Study participants: Healthy volunteers were selected to participate in the study. Ten women and 10 men between the ages of 25 and 60 years were selected to participate in the randomized, double-blind, placebo controlled, cross-over study. Participants lived in the region of Chatsworth, NJ, USA, where the study took place. Participants provided written informed consent prior to study participation, in accordance with Rutgers University Institutional Review Board (IRB) Informed Consent guidelines (protocol # 09-243Mx. Participant exclusion criteria were: current UTI, diabetes, antibiotic use within the previous 6 months, and consumption of a vegetarian diet (due to the high water content of some vegetables and fruits, which could affect urine concentration).
Participants refrained from consuming all cranberry, blueberry, pomegranate, grape, chocolate and other high-flavonoid products for a 7-day run-in period prior to consuming test products and throughout the four, 36-h testing periods, as well as during the 7-day washout period that separated the four 36-h testing periods. Participants restricted the use of alcohol during the test periods. Participants refrained from eating high water content fruits and vegetables during the testing period, and fluid consumption was standardized to 240 mL (including coffee, tea, juice, soda, milk) every 4 h to avoid dilution of urine and to allow for detection of AAA. Participants were instructed not to exercise vigorously during the study period to avoid the excessive loss of body water, which could influence urine concentration.
Test products preparation:
All the test products were prepared in order to ensure a delivery of 36 mg of PACs upon intake of 2 capsules of 500 mg each: (1) HiPAC® BL-DMAC 3.6 EK006178, a cranberry aqueous extract, batch # C220/001/D13, lot#13/226, (2) Cranberry Extract CE15 EK006265, a cranberry hydro-ethanolic extract, batch # C205/013/D13, lot# 13/200D, (3) Cysticran® BL-DMAC 10 EK006267, a blend of (1) and (2), batch # C205/015/D13, lot # 13/200A, (4) Placebo lot#13/200B. Low density STAR-DRI® 1015A maltodextrin was used to standardize all three products to 3.6% PACs. PACs were measured using the validated BL-DMAC method [15] .
Products were administered in the morning in two 500-mg capsules. Placebo capsules contained low density STAR-DRI® 1015A maltodextrin, canola oil, Red 40 Lake, sodium aluminum silicate and Blue 1 Lake. The test and placebo capsules were indistinguishable from each other in appearance.
In vitro anti-adhesion of the test products:
Samples were tested in duplicate for in vitro bacterial AAA on a per weight basis. Samples were suspended (60 mg/mL) in phosphate buffer solution (PBS), neutralized with 1 N NaOH, diluted serially (2-fold), and tested for bacterial AAA utilizing an HRBC hemagglutination assay specific for uropathogenic P-fimbriated E. coli according to a previously described protocol [20] . The procedure was replicated with a second aliquot of product to account for any within-capsule variation. A 30 μL drop of each dilution was incubated with 10 μL of bacterial suspension on a 24-well polystyrene plate for 10 min at room temperature on a rotary shaker. Freshly drawn HRBCs (A1, Rh+) were suspended (3%) in PBS and added separately (10 μL drops) to test suspensions, which were then incubated for 20 min on a rotary shaker at room temperature and evaluated microscopically for the ability to prevent agglutination. The concentration at which hemagglutination activity was suppressed by 50% was recorded as an indicator of the strength of the AAA. Anti-adhesion assays were repeated 3 times and the results averaged. Controls included wells containing bacteria + PBS, HRBC + PBS, bacteria + test compound, HRBC + test compound, and bacteria + HRBC.
Randomization:
To achieve double-blinding of participants and lab personnel, the randomization was performed by the sponsor using an online random sequencing tool (www.random.org, last visited December 31 st , 2014). The products were labeled with a code and the correspondence between the code and test product was kept by the investigator in a sealed envelope and by the sponsor in a password-protected computer until study results were analyzed.
Urine anti-adhesion assay:
For lab processing and testing, urine was thawed, centrifuged, filtered (0.45 μ filter) and tested for pH. Full strength urine samples were used for bacterial AAA utilizing a standard HRBC hemagglutination assay specific for UPEC according to previously described protocol [16] . A 30 μL drop of each urine sample was incubated with 10 μL of a P-fimbriated E. coli strain isolated from a patient with acute pyelonephritis, suspended on a 24-well polystyrene plate for 20 min at room temperature on a rotary shaker. Freshly drawn HRBCs (A1, Rh+) were suspended (3%) in PBS and added separately (10 μL drops) to test suspensions, which were then incubated for 10 min on a rotary shaker at room temperature and evaluated microscopically for the ability to prevent agglutination. The AAA of each urine sample was scored visually based on a quantitative estimation of percent agglutination of each sample using the following scale: 0 = no AAA, 0.5 = 25% AAA, 1 = 50% AAA, 1.5 = 75% AAA, and 2 = 100% AAA. A score of 2 indicates significant AAA in the urine, whereas a score of 1 indicates moderate activity. The detection threshold of the anti-adhesion assay is limited and not high enough to allow quantification of the activity in each urine sample via a dilution series. Anti-adhesion assays were repeated 4 times per sample and the results were averaged. Controls included wells containing bacteria + PBS, HRBCs + PBS, bacteria + test material, HRBCs + test material, and bacteria + HRBCs.
Data analysis:
Observed AAA recorded for all participants over all time periods and by time period, were summed and the 4 treatment conditions were compared using a repeated measure Analysis of Variance (ANOVA). An alpha level of 0.05 was used to define statistical significance. Differences in means were evaluated in comparison with the LSD at the 5% confidence interval level, on the interaction between time and treatment. Any mean difference larger than the LSD was considered for further non-parametric Mann-Whitney-U test (using the Wilcoxon rank sum test to compare all 3 treatment groups versus placebo) to identify which of the group was significantly different from the other with an alphavalue of less than 0.05.
